- Home
- AAMI vs GHRS Comparison
AAMI vs GHRS Comparison
Compare AAMI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- GHRS
- Stock Information
- Founded
- AAMI 1980
- GHRS 2018
- Country
- AAMI United States
- GHRS Ireland
- Employees
- AAMI N/A
- GHRS N/A
- Industry
- AAMI Investment Managers
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AAMI Finance
- GHRS Health Care
- Exchange
- AAMI Nasdaq
- GHRS Nasdaq
- Market Cap
- AAMI 978.8M
- GHRS 868.7M
- IPO Year
- AAMI N/A
- GHRS 2021
- Fundamental
- Price
- AAMI $25.75
- GHRS $12.51
- Analyst Decision
- AAMI Hold
- GHRS Strong Buy
- Analyst Count
- AAMI 1
- GHRS 3
- Target Price
- AAMI $27.00
- GHRS $35.67
- AVG Volume (30 Days)
- AAMI 155.4K
- GHRS 1.1M
- Earning Date
- AAMI 02-06-2025
- GHRS 02-27-2025
- Dividend Yield
- AAMI 0.16%
- GHRS N/A
- EPS Growth
- AAMI 43.23
- GHRS N/A
- EPS
- AAMI 2.22
- GHRS N/A
- Revenue
- AAMI $505,600,000.00
- GHRS N/A
- Revenue This Year
- AAMI $5.10
- GHRS N/A
- Revenue Next Year
- AAMI $7.83
- GHRS N/A
- P/E Ratio
- AAMI $11.56
- GHRS N/A
- Revenue Growth
- AAMI 18.52
- GHRS N/A
- 52 Week Low
- AAMI $21.45
- GHRS $6.00
- 52 Week High
- AAMI $31.52
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- GHRS 51.44
- Support Level
- AAMI N/A
- GHRS $13.50
- Resistance Level
- AAMI N/A
- GHRS $14.91
- Average True Range (ATR)
- AAMI 0.00
- GHRS 1.58
- MACD
- AAMI 0.00
- GHRS -0.22
- Stochastic Oscillator
- AAMI 0.00
- GHRS 5.56
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a diversified, multi-boutique asset management company. It offers institutional investors across the globe access to a wide array of systematic strategies designed to meet a range of risk and return objectives.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.